» Articles » PMID: 26507842

MiR-33a Suppresses Breast Cancer Cell Proliferation and Metastasis by Targeting ADAM9 and ROS1

Overview
Journal Protein Cell
Date 2015 Oct 29
PMID 26507842
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that have a pivotal role in the post-transcriptional regulation of gene expression by sequence-specifically targeting multiple mRNAs. Although miR-33a was recently reported to play an important role in lipid homeostasis, atherosclerosis, and hepatic fibrosis, the functions of miR-33a in tumor progression and metastasis are largely unknown. Here, we found that downregulated miR-33a in breast cancer tissues correlates with lymph node metastasis. MiR-33a expression is significantly lower in the highly metastatic breast cancer cell lines than the noncancerous breast epithelial cells and non-metastatic breast cancer cells. Moreover, the overexpression of miR-33a in metastatic breast cancer cells remarkably decreases cell proliferation and invasion in vitro and significantly inhibits tumor growth and lung metastasis in vivo, whereas its knockdown in non-metastatic breast cancer cells significantly enhances cell proliferation and invasion in vitro and promotes tumor growth and lung metastasis in vivo. Combining bioinformatics prediction and biochemical analyses, we showed that ADAM9 and ROS1 are direct downstream targets of miR-33a. These findings identified miR-33a as a negative regulator of breast cancer cell proliferation and metastasis.

Citing Articles

Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells.

Ahmadi S, Seyedabadi M, Ebrahimnejad P, Abasi M, Nokhodchi A AAPS PharmSciTech. 2024; 25(7):213.

PMID: 39266895 DOI: 10.1208/s12249-024-02906-7.


Ramifications of m6A Modification on ncRNAs in Cancer.

Mehmood R Curr Genomics. 2024; 25(3):158-170.

PMID: 39087001 PMC: 11288162. DOI: 10.2174/0113892029296712240405053201.


Key events in cancer: Dysregulation of SREBPs.

Li Y, Wu S, Zhao X, Hao S, Li F, Wang Y Front Pharmacol. 2023; 14:1130747.

PMID: 36969840 PMC: 10030587. DOI: 10.3389/fphar.2023.1130747.


Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.

Krasniqi E, Goeman F, Pulito C, Palcau A, Ciuffreda L, Di Lisa F Int J Mol Sci. 2022; 23(23).

PMID: 36498861 PMC: 9739115. DOI: 10.3390/ijms232314534.


DLEU7-AS1 promotes renal cell cancer by silencing the miR-26a-5p/coronin-3 axis.

Wang X, Chen L, Xu R, Li S, Luo G Clin Kidney J. 2022; 15(8):1542-1552.

PMID: 35892027 PMC: 9308101. DOI: 10.1093/ckj/sfac061.


References
1.
Rayner K, Esau C, Hussain F, McDaniel A, Marshall S, van Gils J . Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011; 478(7369):404-7. PMC: 3235584. DOI: 10.1038/nature10486. View

2.
Bergethon K, Shaw A, Ou S, Katayama R, Lovly C, McDonald N . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8):863-70. PMC: 3295572. DOI: 10.1200/JCO.2011.35.6345. View

3.
Ibrahim A, Weirauch U, Thomas M, Grunweller A, Hartmann R, Aigner A . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71(15):5214-24. DOI: 10.1158/0008-5472.CAN-10-4645. View

4.
Thomas M, Lange-Grunweller K, Weirauch U, Gutsch D, Aigner A, Grunweller A . The proto-oncogene Pim-1 is a target of miR-33a. Oncogene. 2011; 31(7):918-28. DOI: 10.1038/onc.2011.278. View

5.
Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View